Literature DB >> 8554938

An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype.

S Panserat1, C Mura, N Gérard, M Vincent-Viry, M M Galteau, E Jacoz-Aigrain, R Krishnamoorthy.   

Abstract

1. The study of the CYP2D genotype and phenotype of a Caucasian family revealed that a XbaI-9 kb allele was associated with the poor metabolizer phenotype. 2. A Polymerase Chain Reaction (PCR)-based assay showed that the previously described mutations D6A and D6B are not associated with the XbaI-9 kb allele. 3. To explore the molecular basis of the poor metabolizer phenotype associated with the XbaI-9 kb allele, complete sequencing of the nine exons and intron-exon boundaries of the CYP2D6 gene was undertaken after amplification by PCR. 4. All the exons were successfully amplified using CYP2D6 gene-specific primers except exon 1 which required a combination of CYP2D7 gene-specific 5' primer and a CYP2D6 gene-specific 3' primer. 5. Sequence data derived from this amplified product revealed that the XbaI-9 kb allele corresponds to a novel rearrangement of the locus. This involved a deletion of an approximately 20 kilobase (kb) DNA segment generating a hybrid 5' CYP2D7/CYP2D6 3' gene. 6. The chimeric gene is non-functional presumably due to an insertion in exon 1 (characteristic of the exon 1 of the CYP2D7 gene) which causes a shift in the reading frame with premature termination of translation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8554938      PMCID: PMC1365155          DOI: 10.1111/j.1365-2125.1995.tb04558.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.

Authors:  A K Daly; M Armstrong; S C Monkman; M E Idle; J R Idle
Journal:  Pharmacogenetics       Date:  1991-10

2.  NcoI RFLP in the pseudogene (CYP2D8P) of the human debrisoquine 4-hydroxylase locus.

Authors:  C Mura; J P Broyart; E Jacqz; J Elion; R Krishnamoorthy
Journal:  Nucleic Acids Res       Date:  1991-03-11       Impact factor: 16.971

3.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.

Authors:  G Alván; P Bechtel; L Iselius; U Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.

Authors:  C Mura; N Gerard; M Vincent-Viry; M M Galteau; E Jacqz-Aigrain; R Krishnamoorthy
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

5.  DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers.

Authors:  S Panserat; C Mura; N Gérard; M Vincent-Viry; M M Galteau; E Jacqz-Aigrain; R Krishnamoorthy
Journal:  Hum Genet       Date:  1994-10       Impact factor: 4.132

6.  Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis.

Authors:  A C Gough; C A Smith; S M Howell; C R Wolf; S P Bryant; N K Spurr
Journal:  Genomics       Date:  1993-02       Impact factor: 5.736

7.  A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine.

Authors:  B Evert; E U Griese; M Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-10       Impact factor: 3.000

8.  Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.

Authors:  R Saxena; G L Shaw; M V Relling; J N Frame; D T Moir; W E Evans; N Caporaso; B Weiffenbach
Journal:  Hum Mol Genet       Date:  1994-06       Impact factor: 6.150

9.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

10.  DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.

Authors:  C Mura; S Panserat; M Vincent-Viry; M M Galteau; E Jacqz-Aigrain; R Krishnamoorthy
Journal:  Hum Genet       Date:  1993-10       Impact factor: 4.132

View more
  8 in total

1.  The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements.

Authors:  Andrea Gaedigk; Christa Coetsee
Journal:  Eur J Clin Pharmacol       Date:  2008-01-17       Impact factor: 2.953

2.  Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

Authors:  C Sachse; J Brockmöller; S Bauer; I Roots
Journal:  Am J Hum Genet       Date:  1997-02       Impact factor: 11.025

3.  CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction.

Authors:  Andrea Gaedigk; Uwe Fuhr; Charlene Johnson; L Anick Bérard; Dianne Bradford; J Steven Leeder
Journal:  Pharmacogenomics       Date:  2010-01       Impact factor: 2.533

Review 4.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  CYP2D6: novel genomic structures and alleles.

Authors:  Whitney E Kramer; Denise L Walker; Dennis J O'Kane; David A Mrazek; Pamela K Fisher; Brian A Dukek; Jamie K Bruflat; John L Black
Journal:  Pharmacogenet Genomics       Date:  2009-10       Impact factor: 2.089

6.  Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants.

Authors:  Andrea Gaedigk; Lazara Karelia Montane Jaime; Joseph S Bertino; Anick Bérard; Victoria M Pratt; L Dianne Bradfordand; J Steven Leeder
Journal:  Front Pharmacol       Date:  2010-10-04       Impact factor: 5.810

7.  Molecular evolution of the CYP2D subfamily in primates: purifying selection on substrate recognition sites without the frequent or long-tract gene conversion.

Authors:  Yoshiki Yasukochi; Yoko Satta
Journal:  Genome Biol Evol       Date:  2015-03-25       Impact factor: 3.416

8.  Methodology for clinical genotyping of CYP2D6 and CYP2C19.

Authors:  Beatriz Carvalho Henriques; Avery Buchner; Xiuying Hu; Yabing Wang; Vasyl Yavorskyy; Keanna Wallace; Rachael Dong; Kristina Martens; Michael S Carr; Bahareh Behroozi Asl; Joshua Hague; Sudhakar Sivapalan; Wolfgang Maier; Mojca Z Dernovsek; Neven Henigsberg; Joanna Hauser; Daniel Souery; Annamaria Cattaneo; Ole Mors; Marcella Rietschel; Gerald Pfeffer; Stacey Hume; Katherine J Aitchison
Journal:  Transl Psychiatry       Date:  2021-11-22       Impact factor: 6.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.